Novo Nordisk, a leading pharmaceutical company, is developing CagriSema, a groundbreaking hybrid drug combining semaglutide and cagrilintide, aiming for 25% weight reduction with minimal side effects. This move comes amidst fierce competition from rivals like Eli Lilly, and CagriSema’s success could reshape the obesity treatment landscape.